-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology ELISA Platform: A Powerful Tool to Precisely Analyze Biomolecular Interactions
Author:
InnoModels
Release time:
2024-04-19
Enzyme-linked immunosorbent assay (ELISA) has become a crucial technique in biological science and medical research, and is widely used for the qualitative and quantitative analysis of biomolecules such as proteins, antibodies and antigens. With its unique features, InnoModels Bio's ELISA platform provides researchers with accurate, reliable and efficient testing solutions.
1. High specificity and sensitivity
InnoModels' ELISA platform combines high-quality antigens, antibodies and optimized detection steps to ensure highly specific recognition of target biomolecules. At the same time, through precise signal amplification and detection, the platform realizes highly sensitive detection of biomolecules, allowing accurate results to be obtained even at extremely low concentrations of the target molecule in the sample.
2. Wide applicability
InnoModels' ELISA platform can be applied to the detection of many types of biomolecules, including, but not limited to, proteins, antibodies, antigens, cytokines, hormones, and so on. In addition, the platform supports the detection of a wide range of sample types, such as serum, plasma, cell culture supernatant, tissue homogenate, etc., providing great flexibility for researchers.
3. Reliability and Stability
During the development and production of ELISA kits, InnoModels Biotechnology strictly controls the quality of raw materials, the stability of the production process, and the consistency between batches to ensure the reliability and stability of the test results. Researchers can safely rely on this platform for repetitive experiments and large-scale sample screening.

4. Simple operation process
InnoModels Bio's ELISA platform adopts optimized experimental design and simple operation procedure, which makes the experimental steps easier and faster. Researchers can complete the experimental operation in a short period of time, which improves work efficiency and reduces experimental errors and variability.
5. Quantitative Analysis
In addition to qualitative analysis, InnoModels' ELISA platform also provides accurate quantitative analysis. Through the establishment and analysis of the standard curve, the concentration of the target biomolecule in the sample can be accurately calculated, providing researchers with more detailed data support.
6. Good reproducibility and comparability
InnoModels' ELISA platform emphasizes on the reproducibility of the test results, ensuring good comparability of the test results at different times, in different batches and under different laboratory conditions. This helps researchers to analyze and compare data under different experimental conditions, which improves the reliability and persuasiveness of the research.
Summary
With its high specificity, high sensitivity, broad applicability, reliability and stability, easy operation procedure, quantitative analysis capability, and good reproducibility and comparability, InnoModels' ELISA platform has become a powerful tool for researchers to carry out biomolecular assays. This platform has a promising application in life science, medicine, drug development and other fields, and will play an important role in promoting the progress and development of related fields.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd